Results 1 to 10 of about 38,544 (277)
British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1487-1492, May 2026.While providing potentially life‐saving cardiorespiratory support for critically ill patients, extracorporeal membrane oxygenation (ECMO) may detrimentally affect pharmacokinetic (PK) performance and concurrent drug efficacy and safety. We describe a patient with Pneumocystis jirovecii pneumonia (PJP) in the context of acquired immunodeficiency ...
Tom C. Zwart +7 more
wiley +1 more source
EXPERIENCE WITH DOLUTEGRAVIR IN HIV PATIENTS AT A PUBLIC SECTOR HOSPITAL IN KARACHI, PAKISTAN
Pakistan Armed Forces Medical Journal, 2021 Objective: To study the tolerability and efficacy of dolutegravir in naïve and experienced patients, their management and outcome. Study Design: Cross sectional study. Place and Duration of Study: Ruth KM Pfau Civil Hospital, Karachi Pakistan, from
Farzana Batool +5 more
doaj
Genetic diversity and baseline drug resistance of South African HIV-1 Integrase sequences prior to the availability of Integrase strand-transfer inhibitors [PDF]
, 2020 Dominik Brado
openalex +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1136-1140, May 2026.As antiretroviral therapy (ART) prolongs lifespans, people with HIV (PWH) face a new syndemic: Cardiovascular‐Kidney‐Metabolic (CKM) syndrome. Yet CKM in PWH is poorly characterized. Inflammation, complex pharmacokinetic (PK) alterations, ART‐associated metabolic effects, and gut dysbiosis amplify risk. Managing CKM increases medication burden, thereby
Aaron S. Devanathan, Thomas D. Nolin
wiley +1 more source
Drugs in R & D, 2007 From the discovery of HIV-1 integrase (IN) inhibitors using enzyme-based assays in 1992, it has taken 15 years to achieve success in human clinical trials. Currently available antiretroviral drugs set high clinical standards in efficacy and long-term safety for upcoming novel HIV/AIDS therapeutic agents.
Raveendra, Dayam +2 more
openaire +2 more sources
Infection and Drug Resistance, 2021 Xiaorong Peng,* Yufan Xu,* Ying Huang, Biao Zhu State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China*These ...
Peng X, Xu Y, Huang Y, Zhu B
doaj
Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1179-1194, May 2026.Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott +7 more
wiley +1 more source
Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
Infection and Drug Resistance, 2010 Lisa M Chirch, Roy T SteigbigelDivision of Infectious Diseases, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USAAbstract: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a ...
Lisa M Chirch, Roy T Steigbigel
doaj
Journal of Translational Medicine, 2004 Background CD8+ T cell responses are known to be important to the control of HIV-1 infection. While responses to reverse transcriptase and most structural and accessory proteins have been extensively studied, CD8 T cell responses specifically directed to
Yu Xu G +8 more
doaj +1 more source
Clinical Pharmacology Quality Assurance Program for Global HIV and Co‐Infection Drug Development
Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1205-1215, May 2026.When the acquired immunodeficiency syndrome emerged in the 1980s, the United States National Institutes of Health established research networks to conduct clinical trials with the pharmaceutical industry to identify effective antiretroviral therapeutics.
Robin DiFrancesco +17 more
wiley +1 more source